The Myxedema Coma market size was valued at USD 2.09 billion in 2023 and is expected to exceed USD 3.70 billion by the end of 2036, growing at a CAGR of over 4.5% during the forecast period (i.e. 2024-2036). The Myxedema Coma industry size is expected to be USD 2.17 billion in 2024. The reason behind the growth is the high prevalence of diabetes1. Type 1 diabetes can be associated with other diseases including Hashimoto’s thyroiditis which is considered to be the leading cause of hypothyroidism. Moreover, it causes damage to the thyroid gland and can reduce the levels of thyroid hormones in the body. In 2021, approximately 7 million people worldwide suffer from type 1 diabetes.
The growing geriatric population is believed to drive the growth of the myxedema coma market. Elderly people are more susceptible to thyroid dysfunction and other age-related diseases such as diabetes, which may increase the risk of myxedema coma. Recently, more than 8% of the world population was above the age of 65, and this percentage is expected to rise to around 15% by 2050.
.
.
Growth drivers
challenge
.
.
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
Compound Annual Growth Rate |
~4.5% |
|
Base year market size (2023) |
~ $2.09 billion |
|
Forecasted annual market size (2036) |
~ $3.7 billion |
|
Regional scope |
|
.
.
Route of administration (oral, injection)
The oral segment of the myxedema coma market is expected to gain strong revenue share in the coming years owing to the growing preference for oral treatments. Oral medications carry less risk of problems such as infection or vein damage compared to intravenous treatments. It is believed that approximately 2 in 50 people experience post-injection symptoms within a few hours of receiving an injection. The convenience and cost-effectiveness of oral medications are also driving the growth of the segment.
Distribution channels (hospital pharmacies, retail pharmacies, drug stores, online pharmacies)
The myxedema coma market in the hospital pharmacy segment will soon account for a significant share. Thyroid hormone replacement therapy, which is the medication used to treat myxedema coma, is usually available at hospital pharmacies, where patients can receive this potentially fatal disease. In addition, levothyroxine (T4) and liothyronine (T3) hormones, along with other medications used to treat myxedema coma, are usually taken with the help of a physician. The effectiveness of the patient's treatment must be closely monitored, and the medication dosages altered as needed.
Our in-depth analysis of the global Myxedema Coma market includes the following segments:
|
Route of administration |
|
|
instruct |
|
|
Distribution Channels |
|
|
Drug Category |
|
.
.
North American Market Forecast
North America is expected to account for the largest share of the myxedema coma market at 38% by the end of 2036 owing to the increasing prevalence of obesity. Obesity is a major public health issue in the U.S., affecting more than 30% of Americans. Additionally, obese patients have a higher likelihood of developing hypothyroidism, which, if left untreated, can lead to myxedema coma. The obesity rate in the U.S. is estimated to have increased by more than 2% in 2021 amid the COVID-19 pandemic.
Asia Pacific Market Statistics
The Asia Pacific myxedema coma market is expected to be the second largest market during the forecast period due to the high prevalence of iodine deficiency. One of the most common causes of hypothyroidism globally is iodine deficiency, which is highly prevalent in several countries in the Asia Pacific region, such as South Asia and Southeast Asia. Hence, iodine supplementation and thyroid hormone replacement therapy are gaining popularity in the region.
For example, no state in India is free from iodine deficiency and more than 150 million people are at risk of it.
.
.
.
.
.
作者学分: Radhika Pawar